send petitions, emails, or tweets to world leaders. call governments or join rallies. we offer a variety of ways to make your voice heard...
/
.
why novartis� landmark cancer drug approval is great news for bluebird..
.
loder, who hasn't been involved with any cgrp drug studies, cautions that these medicines don't work for everybody. and they may be risky for some people..
harvard medical school: "cgrp: a new era for migraine treatment.".